Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Congenital factor VII (FVII) deficiency is a rare autosomal recessive coagulation disorder that is characterized by prolongation of prothrombin time. Recombinant activated FVII (rFVIIa) is widely used in the management of bleeding in patients with congenital FVII deficiency. We experienced anesthetic management of a patient with congenital FVII deficiency who was scheduled for laparoscopic colectomy using rFVIIa.
Case Presentation: We report a 67-year-old man with rectal cancer who was diagnosed with congenital FVII deficiency. He was scheduled for laparoscopic colectomy. General anesthesia was performed with propofol, remifentanil, and rocuronium without epidural anesthesia. For coagulation management, 1 mg of rFVIIa was intravenously administered before starting surgery. During surgery, FVII activity and prothrombin time-international normalized ratio (PT-INR) were maintained to be above 10 % and within the normal range (0.8-1.2), respectively. The surgery was uneventfully completed.
Conclusions: We reported successful management of a patient with congenital FVII deficiency undergoing laparoscopic colectomy with monitoring of FVII activity and/or PT-INR.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5814789 | PMC |
| http://dx.doi.org/10.1186/s40981-016-0059-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The importance of incidentally detected coagulation abnormalities in children.
Pediatr Int
August 2025
Department of Pediatric Hematology and Oncology, Ankara City Hospital, Yıldırım Beyazıt University, Cankaya, Turkey.
Background: A history and physical examination can predict most bleeding disorders. This study aimed to reveal possible hemostatic disorders in patients referred to the pediatric hematology department due to the incidentally detected prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT).
Methods: Pediatric patients without known hematologic disease and referred to investigate the incidental prolonged PT and/or aPTT were included.
Low concentrations of recombinant activated factor VII normalize coagulation patterns by reversing the changes in viscoelastic testing parameters induced by abelacimab .
Res Pract Thromb Haemost
July 2025
Hematology Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Background: Low doses of recombinant activated factor (F)VII (rFVIIa), used to manage bleeding in patients with severe FXI deficiency, have been proposed to bypass effects of the FXI/FXIa inhibitor abelacimab.
Objectives: To test whether low concentrations of rFVIIa could abolish changes in coagulation parameters induced by abelacimab as measured by rotational thromboelastometry.
Methods: Whole blood specimens obtained in citrated tubes from 6 healthy donors were incubated with 15 and 30 μg/mL of abelacimab or vehicle for 10 minutes at 37 °C.
Perinatal ischemic stroke in an infant with factor VII deficiency: A CARE-compliant case report.
Medicine (Baltimore)
August 2025
School of Medicine, China Medical University, Taichung, Taiwan.
Rationale: Hemophilia, an inherited bleeding disorder, is rarely caused by congenital factor VII (FVII) deficiency, occurring in 1 in 500,000 patients. Oftentimes, the presenting symptom of newborns with congenital FVII deficiency is intracranial hemorrhage, which can lead to adverse neurological outcomes.
Patient Concerns: A 2-day-old male infant, born late preterm, presented with symptoms of coffee-ground emesis, lethargy, and feeding difficulties.
Genetic and clinical characterization of factor VII deficiency: insights from 34 Turkish patients.
Blood Coagul Fibrinolysis
August 2025
Ege University Faculty of Medicine, Department of Pediatric Genetics, İzmir.
Background: Factor VII (FVII) deficiency is a rare autosomal recessive bleeding disorder caused by pathogenic variants in the F7 gene. Clinical manifestations vary widely, ranging from asymptomatic cases to severe bleeding episodes, including gastrointestinal bleeding and intracranial hemorrhage.
Objective: This study aims to evaluate the clinical and molecular characteristics of Turkish patients diagnosed with FVII deficiency and explore genotype-phenotype correlations.
Sustained high expression of human FVII following AAV8-mediated gene delivery in mice.
Mol Ther Methods Clin Dev
September 2025
Department of Molecular Hematology, Sanquin Research and Landsteiner Laboratory of the Amsterdam UMC, 1066 CX Amsterdam, the Netherlands.
Factor VII (FVII) deficiency is a rare bleeding disorder with a prevalence of approximately 1:300,000-500,000 individuals. We explored whether adeno-associated virus (AAV)-mediated gene therapy can achieve durable and functional expression of human FVII (hFVII) . Wild-type hFVII (hFVIIwt) and a naturally occurring splice variant designated hFVII(-22) (GenBank: NM_019616.
View Article and Find Full Text PDF